
Aspira Women's Health AWH
Quarterly report 2025-Q3
added 11-14-2025
Aspira Women's Health Book Value 2011-2026 | AWH
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Aspira Women's Health
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.73 M | 30.2 M | 9.72 M | 8.74 M | 7.15 M | 3.41 M | 3.76 M | 17.5 M | 19.3 M | 26.8 M | 4.67 M | 10.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 30.2 M | 3.41 M | 12.4 M |
Quarterly Book Value Aspira Women's Health
| 2025-Q3 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.34 M | -60 K | -2.56 M | -2.52 M | -3.71 M | -1.36 M | -2.36 M | -659 K | -528 K | 827 K | 6.98 M | 11.2 M | 14.1 M | 21.7 M | 30.2 M | 38.5 M | 46.8 M | 52.3 M | 9.72 M | 9.72 M | 9.72 M | 9.72 M | 8.74 M | 8.74 M | 8.74 M | 8.74 M | 7.15 M | 7.15 M | 7.15 M | 7.15 M | 3.41 M | 3.41 M | 3.41 M | 3.41 M | 3.76 M | 3.76 M | 3.76 M | 3.76 M | 17.5 M | 17.5 M | 17.5 M | 17.5 M | 19.3 M | 19.3 M | 18.4 M | 19.3 M | 26.8 M | 26.8 M | 26.8 M | 26.8 M | 4.67 M | 4.67 M | 4.67 M | 4.67 M | 10.4 M | 10.4 M | 10.4 M | 10.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 52.3 M | -4.34 M | 11.2 M |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M | ||
|
Anixa Biosciences
ANIX
|
14 M | $ 3.03 | -2.26 % | $ 98.3 K | ||
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M | ||
|
Castle Biosciences
CSTL
|
456 M | $ 39.83 | 1.7 % | $ 1.11 B | ||
|
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | ||
|
Brainsway Ltd.
BWAY
|
75.7 M | $ 23.52 | -2.2 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
1.85 B | $ 34.0 | 0.68 % | $ 366 M | ||
|
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
2.4 B | $ 102.43 | 0.13 % | $ 19 B | ||
|
Fulgent Genetics
FLGT
|
1.13 B | $ 26.13 | -0.44 % | $ 790 M | ||
|
BioNano Genomics
BNGO
|
35.4 M | $ 1.3 | -11.56 % | $ 1.65 M | ||
|
Guardant Health
GH
|
-140 M | $ 111.99 | 1.37 % | $ 13.7 B | ||
|
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M | ||
|
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | ||
|
Co-Diagnostics
CODX
|
86 M | - | - | $ 79.8 M | ||
|
Danaher Corporation
DHR
|
77.5 B | $ 218.32 | -0.59 % | $ 160 B | ||
|
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | ||
|
Lantheus Holdings
LNTH
|
1.09 B | $ 66.61 | -0.1 % | $ 4.61 B | ||
|
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | ||
|
DexCom
DXCM
|
2.07 B | $ 73.22 | -1.05 % | $ 28.3 B | ||
|
NeoGenomics
NEO
|
902 M | $ 11.91 | -3.95 % | $ 1.51 B | ||
|
CareDx, Inc
CDNA
|
261 M | $ 20.33 | -2.26 % | $ 1.09 B | ||
|
Celcuity
CELC
|
116 M | $ 108.09 | -3.59 % | $ 4.26 B | ||
|
DarioHealth Corp.
DRIO
|
96.4 M | $ 10.14 | -1.55 % | $ 288 M | ||
|
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | ||
|
Personalis
PSNL
|
203 M | $ 9.27 | -7.02 % | $ 549 M | ||
|
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
6.3 B | $ 144.04 | -3.77 % | $ 22.9 B | ||
|
QIAGEN N.V.
QGEN
|
6.15 B | - | - | $ 10.6 B | ||
|
IQVIA Holdings
IQV
|
6.07 B | $ 229.24 | -2.71 % | $ 41.6 B | ||
|
Charles River Laboratories International
CRL
|
3.51 B | $ 208.45 | -1.53 % | $ 10.7 B | ||
|
Thermo Fisher Scientific
TMO
|
97.3 B | $ 575.61 | -2.79 % | $ 220 B | ||
|
Trinity Biotech plc
TRIB
|
-35.2 M | $ 0.81 | -7.96 % | $ 61.9 M | ||
|
Twist Bioscience Corporation
TWST
|
473 M | $ 40.92 | -1.59 % | $ 2.45 B | ||
|
Medpace Holdings
MEDP
|
826 M | $ 581.54 | -1.94 % | $ 18 B | ||
|
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 185.97 | 1.99 % | $ 20.6 B | ||
|
Biodesix
BDSX
|
20.9 M | $ 9.61 | -0.57 % | $ 1.25 B | ||
|
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | ||
|
Precipio
PRPO
|
14.4 M | $ 24.39 | 0.54 % | $ 31.7 M | ||
|
Laboratory Corporation of America Holdings
LH
|
8.07 B | $ 269.91 | 0.04 % | $ 22.6 B | ||
|
Mettler-Toledo International
MTD
|
-127 M | $ 1 376.67 | -1.16 % | $ 29.2 B | ||
|
ICON Public Limited Company
ICLR
|
9.52 B | $ 179.26 | -3.57 % | $ 14.8 B | ||
|
IDEXX Laboratories
IDXX
|
1.6 B | $ 673.4 | -0.49 % | $ 55.5 B |